When the science fails and the ethics works: ‘Fail-safe’ ethics in the FEM-PrEP study

References

• 2015. The Oxford English Dictionary. J. Simpson and E. Weiner. Oxford, Oxford University Press.
   Google Scholar
• Annan, K. 2002. In Africa, AIDS Has a Woman's Face. The New York Times. New York: The New York Times Company.
   Google Scholar
• Brown, N., A. Rip, and H. Van Lente. 2003. Expectations in & about Science and Technology. Expectations Workshop. Utrecht: Routledge
   Google Scholar
• Cairns, G. 2009. “The Perils of Success: What if the New Prevention Methods Work?” NAM aidsmap. http://cms.nam.org.uk/site/print/page/1435889/ (last accessed 1st September, 2015)
   Google Scholar
• Carins, G. 2013. “Magical Thinking? FEM-PrEP Trial may have Failed Because Participants used Testing as Prevention.” NAM aidsmap. http://www.aidsmap.com/Magical-thinking-FEM-PrEP-trial-may-have-failed-because-participants-used-testing-as-prevention/page/2695635/ (last accessed 1st September, 2015)
   Google Scholar
• Cohen, J. 2011. “Anti-HIV Pills Powerfully Protect Uninfected Heterosexuals.” Science Mag. http://news.sciencemag.org/health/2011/07/anti-hiv-pills-powerfully-protect-uninfected-heterosexuals (last accessed 1st September, 2015)
   Google Scholar
• Corneli, A. L., K. McKenna, B. Perry, K. Ahmed, K. Agot, F. Malamatsho, J. Skhosana, J. Odhiambo, and L. Van Damme. 2015. “The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills.” J Acquir Immune Defic Syndr 68(5): 578–584.
   PubMed Web of Science ®Google Scholar
• Cornwall, A., E. Harrison, and A. Whitehead. 2007. “Gender Myths and Feminist Fables: The Struggle for Interpretive Power in Gender and Development.” Development and Change 38(1): 1–20.
   Web of Science ®Google Scholar
• Cowan, E. A., and R. Macklin. 2014. “Is Preexposure Prophylaxis Ready for Prime Time use in HIV Prevention Research?” AIDS 28(3): 293–295.
   PubMed Web of Science ®Google Scholar
• Dai, J. Y., C. W. Hendrix, B. A. Richardson, C. Kelly, M. Marzinke, Z. M. Chirenje, J. M. Marrazzo and E. R. Brown (2015). “Pharmacological Measures of Adherence and Risk of HIV Acquisition in the VOICE Study.” Journal of Infectious Diseases j(iv): 333.
   Google Scholar
• FHI. 2011. “FHI Statement on the FEM-PrEP HIV Prevention Study.” fhi360. http://www.fhi360.org/news/fhi-statement-fem-prep-hiv-prevention-study (Last accessed 1st September, 2015)
   Google Scholar
• Geels, F. W., and W. A. Smit. 2000. “Failed Technology Futures: Pitfalls and Lessons from a Historical Survey.” Futures 32(9–10): 867–885.
   Web of Science ®Google Scholar
• Grant, R. M., J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, et al. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men who Have Sex With Men.” N Engl J Med 363(27): 2587–2599.
   PubMed Web of Science ®Google Scholar
• Haire, B., and J. M. Kaldor. 2013. “Ethics of ARV Based Prevention: Treatment-as-Prevention and PrEP.” Developing World Bioethics 13(2): 63–69.
   PubMed Web of Science ®Google Scholar
• Hankins, C. A., and M. R. Dybul. 2013. “The Promise of Pre-Exposure Prophylaxis With Antiretroviral Drugs to Prevent HIV Transmission: A Review.” Curr Opin HIV AIDS 8(1): 50–58.
   PubMed Web of Science ®Google Scholar
• Harper, I., and M. Parker. 2014. “The Politics and Anti-Politics of Infectious Disease Control.” Medical anthropology 33(3): 198–205.
   PubMed Web of Science ®Google Scholar
• Heise, L. L., and C. Elias. 1995. “Transforming AIDS Prevention to Meet Women's Needs: A Focus on Developing Countries.” Social Science & Medicine 40(7): 931–943.
   PubMed Web of Science ®Google Scholar
• Horn, T. 2012. “Poor Adherence Crippled PrEP Efficacy in Women's Study.” AIDSMeds. http://www.aidsmeds.com/articles/hiv_prep_women_1667_22021.shtml (Last accessed 1st September, 2015).
   Google Scholar
• Karim, S. S. A., and Q. A. Karim. 2011. “Antiretroviral Prophylaxis: A Defining Moment in HIV Control.” The Lancet 378(9809): e23–e25.
   PubMed Web of Science ®Google Scholar
• Kenworthy, N. J., and N. Bulled. 2013. “From Modeling to Morals: Imagining the Future of HIV PREP in Lesotho.” Dev World Bioeth 13(2): 70–78.
   PubMed Web of Science ®Google Scholar
• Lange, J. M. A. 2005. “We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV.” PLoS Medicine 2(9): e248.
   PubMed Web of Science ®Google Scholar
• Marrazzo, J. M., G. Ramjee, B. A. Richardson, K. Gomez, N. Mgodi, G. Nair, T. Palanee, et al. 2015. “Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women.” New England Journal of Medicine 372(6): 509–518.
   PubMed Web of Science ®Google Scholar
• Mascolini, M. 2012. Poor Adherence May Explain FEM-PrEP Failure to Find Protection from HIV with Truvada. 19th Conference on Retroviruses and Opportunistic Infections. Seattle.
   Google Scholar
• McGoey, L. 2010. “Profitable Failure: Antidepressant Drugs and the Triumph of Flawed Experiments.” History of the Human Sciences 23(1): 58–78.
   PubMed Web of Science ®Google Scholar
• McNeil, G. D. 2015. A Failed Trial in Africa Raises Questions About How to Test HIV Drugs. The New York Times. New York, The New York Times Company.
   Google Scholar
• Meier, B. M., K. N. Brugh, and Y. Halima. 2012. “Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy.” Public Health Ethics 5(3): 263–282.
   PubMed Web of Science ®Google Scholar
• Michael, M., and N. Brown. 2003. Dys-Topias and Dys-Tropias: Futures and Performativities in Xenotransplantation. The annual British Sociology Association Conference. University of York.
   Google Scholar
• Montgomery, C. M. 2012. “Making Prevention Public: The Co-production of Gender and Technology in HIV Prevention Research.” Social Studies of Science 42(6): 922–944.
   Web of Science ®Google Scholar
• Nyamu-Musembi, C., and A. Cornwall. 2004. “What is the ‘Rights-based Approach’ all about?: Perspectives from International Development Agencies.” IDS Working Paper 234.
   Google Scholar
• Petryna, A., L. Andrew, and K. Arthur. 2006. Global Pharmaceuticals: Ethics, Markets, Practices.. Durham, N.C., Duke University Press.
   Google Scholar
• Rhodes, T., S. Bernays, and K. J. Terzić. 2009. “Medical Promise and the Recalibration of Expectation: Hope and HIV Treatment Engagement in a Transitional Setting.” Social Science & Medicine 68(6): 1050–1059.
   PubMed Web of Science ®Google Scholar
• Rosengarten, M., and M. Michael. 2009. “The Performative Function of Expectations in Translating Treatment to Prevention: The Case of HIV Pre-exposure Prophylaxis, or PrEP.” Social Science & Medicine 69(7): 1049–1055.
   PubMed Web of Science ®Google Scholar
• Rosengarten, M., and M. Michael. 2009. “Rethinking the Bioethical Enactment of Medically Drugged Bodies: Paradoxes of Using Anti-HIV Drug Therapy as a Technology for Prevention.” Science as Culture 18(2): 183–199.
   Web of Science ®Google Scholar
• Stanley, L., and S. Wise. 1993. Breaking Out Again: Feminist Ontology and Epistemology London, Routledge.
   Google Scholar
• Susser, I. 2015. Blame Research Design for Failed HIV Study. Al Jazeera America. New York, Al Jazeera Media Network.
   Google Scholar
• Uvin, P. 2002. “On High Moral Ground: The Incorporation of Human Rights by the Development Enterprise.” Praxis: The Fletcher Journal of Development Studies 17: 1–11.
   Google Scholar
• Walker, B. D., and D. R. Burton. 2008. “Toward an AIDS Vaccine.” Science 320(5877): 760–764.
   PubMed Web of Science ®Google Scholar
• Wong, C., C. Parker, K. Ahmed, K. Agot, J. Skhosana2, J. Odhiambo3, S. Makatu, et al. 2013. Participant Motivation for Enrolling and Continuing in the FEM-PrEP HIV Prevention Clinical Trial. Seventh International AIDS Society Conference on HIV Pathogenesis. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur.
   Google Scholar